Google-backed AI drug discovery company XtalPi has collaborated with cancer-focused biotechnology company Parthenon Therapeutics to discover therapeutic antibodies for solid tumors. The terms and financial details have not been disclosed.
The partnership will leverage XtalPi's XupremAb antibody discovery platform, which utilizes AI and wet lab techniques to generate antibody candidates. The collaboration aims to develop next-generation cancer therapeutics by leveraging Parthenon's tumor microenvironment (TME) expertise and XtalPi's AI capabilities in antibody discovery.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.